ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: INFO06

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

Session Information

  • Informational Posters
    October 25, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category:

  • No subcategory defined

Authors

  • Palmer, Nicholette D., Wake Forest School of Medicine, Winston-Salem, North Carolina, United States
  • Alexander, Amir, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States
  • Russell, Laurie P., Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
  • Smith, Carrie, Wake Forest Universtiy Health Sciences, Winston Salem, North Carolina, United States
  • Kimmel, Paul L., National Institute of Diabetes and Digestive Kidney Diseases (NIDDK), Bethesda, Maryland, United States
  • Reboussin, David, Wake Forest University Sch of Med, Winston-Salem, North Carolina, United States
  • Freedman, Barry I., Wake Forest School of Medicine, Winston-Salem, North Carolina, United States

Group or Team Name

  • APOLLO Investigators
Description

The NIH-sponsored APOLLO study will prospectively assess outcomes after kidney transplantation from donors with recent African ancesty based on their apolipoprotein 1 (APOL1) genotypes. Eligible donors include African Americans, Hispanic blacks, Afro-Caribbeans and Africans. APOLLO will also assess the safety of living kidney donation based on APOL1 genotypes.

Funding

  • NIH